Literature DB >> 33925884

Role of Immune Checkpoint Inhibitors in Cervical Cancer: From Preclinical to Clinical Data.

Simona Duranti1, Antonella Pietragalla1, Gennaro Daniele1, Camilla Nero1,2, Francesca Ciccarone2, Giovanni Scambia1,3, Domenica Lorusso1,3.   

Abstract

Human papillomavirus (HPV) infection is the recognized cause of almost all cervical cancers. Despite the reduction in incidence due to a wide use of screening programs and a specific vaccine, the prognosis of cervical cancer remains poor, especially for late-stage and relapsed disease. Considering the elevated rates of PD-L1 expression in up to 80% of cervical cancers, a strong rationale supports the use of immunotherapy to restore the immune response against tumor. The aim of this review is to analyze the possible role of immune checkpoint inhibitors in cervical cancer treatment, with a particular focus on the rationale and on the results of phase I and II clinical trials. An overview of ongoing phase III studies with possible future areas of development is also provided.

Entities:  

Keywords:  CTLA4; PD-1; PD-L1; cervical cancer; immune checkpoint inhibitors; immunotherapy

Year:  2021        PMID： 33925884     DOI： 10.3390/cancers13092089

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN： 2072-6694            Impact factor:   6.639


  40 in total

1.  Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  N Colombo; S Carinelli; A Colombo; C Marini; D Rollo; C Sessa
Journal:  Ann Oncol       Date:  2012-10       Impact factor: 32.976

Review 2.  Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape.

Authors:  Leisha A Emens; Paolo A Ascierto; Phillip K Darcy; Sandra Demaria; Alexander M M Eggermont; William L Redmond; Barbara Seliger; Francesco M Marincola
Journal:  Eur J Cancer       Date:  2017-06-15       Impact factor: 9.162

3.  Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.

Authors:  M Morris; P J Eifel; J Lu; P W Grigsby; C Levenback; R E Stevens; M Rotman; D M Gershenson; D G Mutch
Journal:  N Engl J Med       Date:  1999-04-15       Impact factor: 91.245

4.  Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.

Authors:  P G Rose; B N Bundy; E B Watkins; J T Thigpen; G Deppe; M A Maiman; D L Clarke-Pearson; S Insalaco
Journal:  N Engl J Med       Date:  1999-04-15       Impact factor: 91.245

5.  Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.

Authors:  C W Whitney; W Sause; B N Bundy; J H Malfetano; E V Hannigan; W C Fowler; D L Clarke-Pearson; S Y Liao
Journal:  J Clin Oncol       Date:  1999-05       Impact factor: 44.544

6.  Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial.

Authors:  Jean-Sebastien Frenel; Christophe Le Tourneau; Bert O'Neil; Patrick A Ott; Sarina A Piha-Paul; Carlos Gomez-Roca; Emilie M J van Brummelen; Hope S Rugo; Shari Thomas; Sanatan Saraf; Reshma Rangwala; Andrea Varga
Journal:  J Clin Oncol       Date:  2017-11-02       Impact factor: 44.544

7.  PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.

Authors:  Dung T Le; Jennifer N Uram; Hao Wang; Bjarne R Bartlett; Holly Kemberling; Aleksandra D Eyring; Andrew D Skora; Brandon S Luber; Nilofer S Azad; Dan Laheru; Barbara Biedrzycki; Ross C Donehower; Atif Zaheer; George A Fisher; Todd S Crocenzi; James J Lee; Steven M Duffy; Richard M Goldberg; Albert de la Chapelle; Minori Koshiji; Feriyl Bhaijee; Thomas Huebner; Ralph H Hruban; Laura D Wood; Nathan Cuka; Drew M Pardoll; Nickolas Papadopoulos; Kenneth W Kinzler; Shibin Zhou; Toby C Cornish; Janis M Taube; Robert A Anders; James R Eshleman; Bert Vogelstein; Luis A Diaz
Journal:  N Engl J Med       Date:  2015-05-30       Impact factor: 91.245

8.  Expression of PD-L1 and presence of CD8-positive T cells in pre-treatment specimens of locally advanced cervical cancer.

Authors:  Emeka K Enwere; Elizabeth N Kornaga; Michelle Dean; Theodora A Koulis; Tien Phan; Maria Kalantarian; Martin Köbel; Prafull Ghatage; Anthony M Magliocco; Susan P Lees-Miller; Corinne M Doll
Journal:  Mod Pathol       Date:  2017-01-06       Impact factor: 7.842

9.  Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study.

Authors:  David H Moore; John A Blessing; Richard P McQuellon; Howard T Thaler; David Cella; Jo Benda; David S Miller; George Olt; Stephanie King; John F Boggess; Thomas F Rocereto
Journal:  J Clin Oncol       Date:  2004-08-01       Impact factor: 44.544

10.  CALLA: Efficacy and safety of concurrent and adjuvant durvalumab with chemoradiotherapy versus chemoradiotherapy alone in women with locally advanced cervical cancer: a phase III, randomized, double-blind, multicenter study.

Authors:  Jyoti Mayadev; Ana T Nunes; Mary Li; Michelle Marcovitz; Mark C Lanasa; Bradley J Monk
Journal:  Int J Gynecol Cancer       Date:  2020-05-23       Impact factor: 3.437
View more
  3 in total

1.  Development of a Novel Immune Infiltration-Based Gene Signature to Predict Prognosis and Immunotherapy Response of Patients With Cervical Cancer.

Authors:  Sihui Yu; Xi Li; Jiawen Zhang; Sufang Wu
Journal:  Front Immunol       Date:  2021-09-03       Impact factor: 7.561

Review 2.  Cervical cancer therapies: Current challenges and future perspectives.

Authors:  Carly A Burmeister; Saif F Khan; Georgia Schäfer; Nomonde Mbatani; Tracey Adams; Jennifer Moodley; Sharon Prince
Journal:  Tumour Virus Res       Date:  2022-04-20

3.  Immune and inflammation: related factor alterations as biomarkers for predicting prognosis and responsiveness to PD-1 monoclonal antibodies in cervical cancer.

Authors:  Xihan Liu; Xi Zhang; Chang Liu; Wendi Mu; Jin Peng; Kun Song
Journal:  Discov Oncol       Date:  2022-09-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.